MLYS:NASDAQ, Mineralys Therapeutics, Inc.

MLYS stock overview

Mineralys Therapeutics, Inc. (MLYS:NASDAQ) closed at $13.66 on November 20, 2026, down 3.53% on the day. The stock trades 69.0% below its 52-week high of $44.13 and 0.7% above its 52-week low of $13.57. Over the past year, it lost 67.9%. Mineralys Therapeutics, Inc. is part of the Health Care sector.

Key figures

Price
$13.66
Day change
-3.53%
Volume
1,345,618
Average volume
1,542,484
Market cap
1B+
52-week range
$13.57 – $44.13
50-day average
$21.42
200-day average
$25.82

Price action over the past year

In 252 trading sessions since November 20, 2025, MLYS closed higher on 108 days (43%). Its best day was March 31, 2026 (+15.23%) and its worst was November 2, 2026 (-14.47%). The stock moved 10% or more in a single session 8 times.

Recent signals

MLYS news

About Mineralys Therapeutics, Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.

Similar stocks

Find more stocks like MLYS with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.